Suppr超能文献

《中国地中海贫血铁螯合治疗指南(2025年版)》

[Guidelines for iron chelation therapy in thalassemia in China (2025)].

出版信息

Zhongguo Dang Dai Er Ke Za Zhi. 2025 Apr 15;27(4):377-388. doi: 10.7499/j.issn.1008-8830.2411001.

Abstract

Iron overload is a major complication of thalassemia, clinically manifested as heart failure, liver cirrhosis, diabetes, growth and development retardation, and delayed sexual development, with severe cases leading to death. Standardized iron chelation therapy is essential to ensure long-term and high-quality survival for patients. This guideline provides recommendations on methods for detecting iron overload, the timing for initiating iron chelation therapy, treatment strategies for transfusion-dependent and non-transfusion-dependent thalassemia, and special circumstances regarding iron chelation therapy, serving as a reference for iron chelation treatment in thalassemia.

摘要

铁过载是地中海贫血的主要并发症,临床表现为心力衰竭、肝硬化、糖尿病、生长发育迟缓以及性发育延迟,严重时可导致死亡。标准化的铁螯合治疗对于确保患者长期高质量生存至关重要。本指南就铁过载的检测方法、开始铁螯合治疗的时机、输血依赖型和非输血依赖型地中海贫血的治疗策略以及铁螯合治疗的特殊情况提供了建议,为地中海贫血的铁螯合治疗提供参考。

相似文献

1
[Guidelines for iron chelation therapy in thalassemia in China (2025)].
Zhongguo Dang Dai Er Ke Za Zhi. 2025 Apr 15;27(4):377-388. doi: 10.7499/j.issn.1008-8830.2411001.
2
Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.
Blood Cells Mol Dis. 2014 Feb-Mar;52(2-3):88-90. doi: 10.1016/j.bcmd.2013.08.006. Epub 2013 Sep 13.
3
Iron Chelation Therapy as a Modality of Management.
Hematol Oncol Clin North Am. 2018 Apr;32(2):261-275. doi: 10.1016/j.hoc.2017.12.002. Epub 2018 Jan 17.
6
Iron Chelation for Iron Overload in Thalassemia.
Met Ions Life Sci. 2019 Jan 14;19. doi: 10.1515/9783110527872-009.
8
MRI and iron-overload cardiomyopathy in thalassaemia.
Circulation. 2006 Mar 21;113(11):f43-4.
9
Rapid iron loading in a pregnant woman with transfusion-dependent thalassemia after brief cessation of iron chelation therapy.
Eur J Haematol. 2008 Aug;81(2):157-9. doi: 10.1111/j.1600-0609.2008.01092.x. Epub 2008 May 6.
10
Assessment and treatment of cardiac iron overload in thalassemia.
Hemoglobin. 2009;33 Suppl 1:S87-92. doi: 10.3109/03630260903347401.

本文引用的文献

1
Thalassemia and iron overload cardiomyopathy: Pathophysiological insights, clinical implications, and management strategies.
Curr Probl Cardiol. 2025 Jan;50(1):102911. doi: 10.1016/j.cpcardiol.2024.102911. Epub 2024 Oct 28.
2
Management of iron overload: lessons from transfusion-dependent hemoglobinopathies.
Blood. 2025 Jan 23;145(4):359-371. doi: 10.1182/blood.2023022502.
3
Anemia and iron overload as prognostic markers of outcomes in β-thalassemia.
Expert Rev Hematol. 2024 Sep;17(9):631-642. doi: 10.1080/17474086.2024.2383420. Epub 2024 Jul 26.
6
Epidemiology of clinically significant forms of alpha- and beta-thalassemia: A global map of evidence and gaps.
Am J Hematol. 2023 Sep;98(9):1436-1451. doi: 10.1002/ajh.27006. Epub 2023 Jun 26.
8
[Chinese guideline for diagnosis and treatment of transfusion dependent β-thalassemia (2022)].
Zhonghua Xue Ye Xue Za Zhi. 2022 Nov 14;43(11):889-896. doi: 10.3760/cma.j.issn.0253-2727.2022.11.002.
10
The Long-Term Efficacy of Deferiprone in Thalassemia Patients With Iron Overload: Real-World Data from the Registry Database.
Hemoglobin. 2022 Mar;46(2):75-80. doi: 10.1080/03630269.2022.2072326. Epub 2022 Aug 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验